Source: Health Products Regulatory Authority (ZA) Publisher: Biotech Laboratories (Pty) Ltd, Ground Floor, Block K West, Central Park, 400 16<sup>th</sup> Street, Randjespark, Midrand 1685, South Africa, Tel. nr: 011 848 3050
TRANMENXIO IV.
| Pharmaceutical Form |
|---|
|
Solution for injection/infusion. Clear, colourless solution with pH of 6,5-8,0. |
Each 5 ml ampoule contains 500 mg Tranexamic acid.
Sugar free.
For a full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. |
| List of Excipients |
|---|
|
Water for injection |
5 ml type 1 clear glass ampoules, 5 such ampoules are placed in tray and packed in carton.
Biotech Laboratories (Pty) Ltd, Ground Floor, Block K West, Central Park, 400 16th Street, Randjespark, Midrand 1685, South Africa, Tel. nr: 011 848 3050
56/8.1/0497
29 March 2022
| Drug | Countries | |
|---|---|---|
| TRANMENXIO | South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.